What is endosomal escape in oligonucleotide therapeutics?
Endosomal escape refers to the process by which internalized oligonucleotides exit endosomal vesicles
and gain access to the cytosol or nucleus, where they can engage RNA targets or protein complexes.
In most systems, only a small fraction of internalized material becomes functionally active,
making chemical and conjugation engineering central to therapeutic design.
After endocytic uptake, therapeutic oligonucleotides (siRNA, ASO, miRNA, SSO) are typically sequestered within early and late endosomes, with only a small fraction reaching the cytosol or nucleus1. In many programs, endosomal escape—not binding affinity—is the dominant limiter of functional potency2.
“Escape” is not a single event but a probability distribution influenced by vesicle trafficking, membrane composition, ionization state, and cargo properties. Practical engineering focuses on increasing the odds of productive cytosolic exposure by tuning:
membrane interaction, intracellular stability, charge behavior, and triggered release.
Bio‑Synthesis provides a CDMO‑style chemistry platform to build and validate escape‑oriented architectures—conjugates, linkers, backbones, and 2′ chemistries—plus compatibility with external formulation systems (e.g., ionizable LNP).
Key constraint
Typical
Escape efficiency
Often ~1–2% functional release; engineering increases probability, not certainty.
Design levers
Layered
Architecture stack
Backbone + 2′ chemistry + conjugation + linker triggers + formulation compatibility.
Backbone: PS / PN / mixed architectures
2′ sugar: 2′‑OMe • 2′‑F • 2′‑MOE
Locked/bridged: LNA • BNA • NMP
Neutral scaffolds: PMO • PNA
Conjugation: CPP • EEP/HA2/GALA • lipids • GalNAc
Cleavable linkers: disulfide • acid‑cleavable
Formulation‑compatible: ionizable LNP builds